No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BPTH Bio-Path Holdings
- 2.270
- -0.120-5.02%
Close Jun 18 16:00 ET
- 2.230
- -0.040-1.76%
Post 19:51 ET
4.72MMarket Cap-89P/E (TTM)
2.420High2.250Low91.90KVolume2.420Open2.390Pre Close213.13KTurnover4.43%Turnover RatioLossP/E (Static)2.08MShares36.40052wk High-1.80P/B4.71MFloat Cap1.85052wk Low--Dividend TTM2.08MShs Float23999.988Historical High--Div YieldTTM7.13%Amplitude1.850Historical Low2.319Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion by 2029 as Clinical Trials Increase
Roth MKM Maintains Bio-Path Holdings(BPTH.US) With Buy Rating, Maintains Target Price $20
Roth MKM analyst Jonathan Aschoff maintains $Bio-Path Holdings(BPTH.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 0.0% and
Express News | Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
Why Bio-Path Stock Is Climbing Today
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax
Market-Moving News for June 14th
ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance.BPTH: 46% | Bio-Path Holdings shares are trading higher after the company announced interim r
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards
Comments
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress.
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
1
$Bio-Path Holdings(BPTH.US$
Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
1
4
$Bio-Path Holdings(BPTH.US$
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combinati...
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combinati...
2
$Bio-Path Holdings(BPTH.US$ Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced at-the-Market Under Nasdaq Rules
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg